keyword
MENU ▼
Read by QxMD icon Read
search

hyperthermic intraperitoneal chemotherapy

keyword
https://www.readbyqxmd.com/read/28650573/factors-associated-with-thromboembolic-events-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#1
Amihai Rottenstreich, Yosef Kalish, Geffen Kleinstern, Almog Ben Yaacov, Joseph Dux, Aviram Nissan
BACKGROUND AND OBJECTIVES: We investigated the risk factors, incidence, and role of thromboprophylaxis in the development of thrombosis following cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). METHODS: We reviewed data of patients with CRS/HIPEC in three hospitals. RESULTS: Overall, 192 patients underwent CRS/HIPEC during 2007-2016. Mechanical (thigh-length pneumatic compression stockings) and pharmacologic thromboprophylaxis (40 mg enoxaparin daily, starting 12 h before surgery until discharge) was provided for all patients; and 116 (60...
June 26, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28643069/lessons-learned-from-a-phase-ii-clinical-trial-of-laparoscopic-hipec-for-gastric-cancer
#2
Brian Badgwell, Mariela Blum, Prajnan Das, Jeannelyn Estrella, Xuemei Wang, Keith Fournier, Richard Royal, Paul Mansfield, Jaffer Ajani
BACKGROUND: Over the last two decades, intraperitoneal chemotherapy has been found to have activity for select subgroups of patients with carcinomatosis from colon, ovarian, appendiceal, and recently, gastric origins. However, there is little data to support an aggressive surgical approach of cytoreduction (debulking) and hyperthermic intraperitoneal perfusion with chemotherapy (HIPEC) for patients with gastric cancer and positive cytology or carcinomatosis. The morbidity and mortality rates of cytoreduction and HIPEC, in combination with gastrectomy, are significant and the survival rates of this approach may not extend beyond that of treatment with systemic chemotherapy...
June 22, 2017: Surgical Endoscopy
https://www.readbyqxmd.com/read/28637567/the-impact-of-early-recurrence-on-quality-of-life-after-cytoreduction-with-hipec
#3
Nathan M Hinkle, Vandana Botta, John P Sharpe, Paxton Dickson, Jeremiah Deneve, Gitonga Munene
Improved oncological outcomes after cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) in highly selected patients have been well documented. The extensive nature of the procedure adversely affects quality of life (QoL). The aim of this study is to longitudinally evaluate QoL following CRS/HIPEC. This is a retrospective review of a prospectively maintained database of patients with peritoneal malignancies undergoing CRS/HIPEC. Clinicopathological data, oncologic outcomes, and QoL were analyzed preoperatively and postoperatively at 2 weeks, and 1, 3, 6, and 12 months...
June 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28633580/platinum-agents-and-mitomycin-c-specific-complications-in-cytoreductive-surgery-crs-and-hyperthermic-intraperitoneal-chemotherapy-hipec
#4
Grace Hwei Ching Tan, Nicholas B Shannon, Claramae Shulyn Chia, Khee Chee Soo, Melissa Ching Ching Teo
INTRODUCTION: Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) have been found to prolong survival in patients with peritoneal disease but is associated with significant morbidity. We evaluate the perioperative complications and the association with the chemotherapy agent used for HIPEC. METHODS: Retrospective analysis of a prospectively collected database of CRS-HIPEC cases between April 2001 and February 2016 was performed. Patients were stratified by the chemotherapy used, and perioperative complications were compared...
June 20, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28628712/hyperthermic-intraperitoneal-chemoperfusion-as-a-component-of-multimodality-therapy-for-ovarian-and-primary-peritoneal-cancer
#5
Deepa Magge, Lekshmi Ramalingam, Yongli Shuai, Robert P Edwards, James F Pingpank, Steven S Ahrendt, Matthew P Holtzman, Herbert J Zeh, David L Bartlett, Haroon A Choudry
BACKGROUND AND OBJECTIVES: The role of hyperthermic intraperitoneal chemoperfusion (HIPEC) in the multimodality treatment of ovarian peritoneal metastases (OPM) and primary peritoneal cancer (PPC) remains controversial. We hypothesized that cytoreductive surgery (CRS) and HIPEC would provide meaningful survival benefit without excessive morbidity. METHODS: We reviewed clinicopathologic and perioperative data following 96 CRS-HIPEC procedures for primary or recurrent OPM and PPC...
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28624046/failure-to-rescue-following-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#6
Kevin Y Li, Ali A Mokdad, Rebecca M Minter, John C Mansour, Michael A Choti, Mathew M Augustine, Patricio M Polanco
BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) can significantly improve the survival in selected patients with peritoneal carcinomatosis. This study aims to identify perioperative patient characteristics predictive of failure to rescue (FTR), mortality following postoperative complications from CRS/HIPEC. METHODS: Patients suffering a complication following CRS/HIPEC between 2005 and 2013 were identified in the American College of Surgeons National Surgical Quality Improvement Program data set...
June 15, 2017: Journal of Surgical Research
https://www.readbyqxmd.com/read/28622839/water-lavage-as-an-adjunct-to-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-crs-hipec
#7
Emmanuel Gabriel, Smit Singla, Minhyung Kim, Daniel Fisher, Colin Powers, Anthony Visioni, Kristopher Attwood, Joseph Skitzki
BACKGROUND: Water lavage (WL) during gastrointestinal cancer surgery has osmotically mediated lytic effects on tumor cells. We investigated the safety and efficacy of WL with CRS-HIPEC. METHODS: This is a retrospective review, 1/2003-7/2014, of a single institution experience with CRS-HIPEC comparing patients who had WL (WL+) to those who did not (WL-). RESULTS: Of 157 CRS-HIPECs, 16 (10.2%) were WL+. WL+ had more PCI scores >20 compared to WL- (56...
June 6, 2017: American Journal of Surgery
https://www.readbyqxmd.com/read/28619621/immunohistochemical-evaluation-of-two-antibodies-against-pd-l1-and-prognostic-significance-of-pd-l1-expression-in-epithelioid-peritoneal-malignant-mesothelioma-a%C3%A2-renape-study
#8
S Valmary-Degano, P Colpart, L Villeneuve, F Monnien, L M'Hamdi, G Lang Averous, M Capovilla, F Bibeau, M-H Laverriere, V Verriele-Beurrier, H Ben Rejeb, P Dartigues, J Hommell-Fontaine, F-N Gilly, S Isaac, E Mery
BACKGROUND: Epithelioid peritoneal malignant mesothelioma (EPMM) is the most common subtype of this aggressive tumor. We compared two antibodies against PD-L1, a recent theranostic biomarker, and evaluated the prognostic value of PD-L1 expression by mesothelial and immune cells in EPMM. METHODS: Immunohistochemistry was performed on 45 EPMM. Clinical and pathological data were extracted from the RENAPE database. Using E1L3N and SP142 clones, inter-observer agreement, PD-L1 expression by mesothelial and immune cells and inter-antibody agreement were evaluated...
May 18, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28612016/oligometastatic-disease-in-the-peritoneal-space-with-gastrointestinal-cancer
#9
REVIEW
Beate Rau, Andreas Brandl, Andreas Pascher, Wieland Raue, Paul Sugarbaker
OBJECTIVES: Treatment options for patients with gastrointestinal cancer and oligometastastic disease remain the domain of the medical oncologist. However, in selected cases, attempts to remove or destroy the tumor burden seem appropriate. BACKGROUND DATA: During the last decade, the treatment of localized and isolated tumor nodules, such as lung, liver or peritoneal metastasis, has changed. Previously, these patients with metastatic disease only received palliative chemotherapy...
March 2017: Visceral Medicine
https://www.readbyqxmd.com/read/28608388/interval-between-cytoreductions-as-a-marker-of-tumor-biology-in-selecting-patients-for-repeat-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#10
Ioannis T Konstantinidis, Edward A Levine, Konstantinos Chouliaras, Gregory Russell, Perry Shen, Konstantinos I Votanopoulos
BACKGROUND AND OBJECTIVES: Repeat cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) for recurrence of peritoneal surface malignancies is safe and effective. Patient selection and factors associated with a favorable outcome are still evolving. METHODS: A prospectively maintained institutional database consisting of 1314 CRS/HIPEC procedures performed between February 1993 and December 2015 was reviewed. Clinicopathologic data from 103 patients and 112 (8...
June 12, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28607791/benign-multicystic-peritoneal-mesothelioma-a-rare-condition-in-an-uncommon-gender
#11
Muhammad S Khurram, Hamadullah Shaikh, Uqba Khan, Jacob Edens, Warda Ibrar, Ameer Hamza, Awais Zaka, Roohi Bano, Tarik Hadid
Benign Multicystic Peritoneal Mesothelioma (BMPM) is a rare condition that arises from the abdominal peritoneum. Fewer than 200 cases have been reported worldwide. BMPM usually affects premenopausal women and is extremely rare in men. Many factors are suspected to contribute to its development, such as previous surgery, endometriosis, and familial Mediterranean fever. The main management is surgical resection; however, it is estimated that the recurrence rate is up to 50%. Malignant transformation is rare. We report a case series of three male patients who were diagnosed with BMPM and were treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC)...
2017: Case Reports in Pathology
https://www.readbyqxmd.com/read/28598731/neoplasms-of-the-appendix-pictorial-review-with-clinical-and-pathologic-correlation
#12
Laura M Leonards, Anokh Pahwa, Maitraya K Patel, Jeffrey Petersen, Michael J Nguyen, Cecilia M Jude
Appendiceal neoplasms are uncommon tumors of the gastrointestinal tract that may manifest with symptoms of appendicitis, right lower quadrant pain, or palpable mass, leading to imaging or surgical intervention. The majority of appendiceal masses consist of primary epithelial neoplasms and neuroendocrine tumors (NETs). Epithelial neoplasms-mucinous and nonmucinous types-are more often detected at imaging than NETs due to their larger size and propensity for peritoneal spread and metastatic disease. Epithelial mucinous neoplasms are defined by the presence of mucin, detected at radiologic and pathologic examination...
June 9, 2017: Radiographics: a Review Publication of the Radiological Society of North America, Inc
https://www.readbyqxmd.com/read/28595688/the-efficacy-of-dextran-40-as-a-venous-thromboembolism-prophylaxis-strategy-in-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy
#13
R Sleightholm, D Watley, S Wahlmeier, A Patel, J M Foster
No abstract text is available yet for this article.
May 1, 2017: American Surgeon
https://www.readbyqxmd.com/read/28594718/risk-of-ovarian-involvement-in-advanced-colorectal-or-appendiceal-tumors-involving-the-peritoneum
#14
Akash M Mehta, Mark B Bignell, Sue Alves, Sanjeev P Dayal, Faheez Mohamed, Tom D Cecil, Brendan J Moran
BACKGROUND: Ovarian metastases of GI tumors grow rapidly and are relatively resistant to systemic chemotherapy. They may be unilateral or bilateral and macroscopic or occult. The risk of macroscopic ovarian involvement or occult involvement of macroscopically normal ovaries is unquantified. OBJECTIVE: This study aims to quantify the risks of ovarian involvement in patients with peritoneal malignancy undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy...
July 2017: Diseases of the Colon and Rectum
https://www.readbyqxmd.com/read/28594258/first-line-chemotherapy-with-pemetrexed-plus-cisplatin-for-malignant-peritoneal-mesothelioma
#15
Eriko Fujimoto, Takashi Kijima, Kozo Kuribayashi, Yoshiki Negi, Shingo Kanemura, Koji Mikami, Hiroshi Doi, Kazuhiro Kitajima, Takashi Nakano
BACKGROUND: Mesothelioma of peritoneal origin has wider variation in treatment outcomes than mesothelioma of pleural origin, likely because peritoneal mesothelioma comprises borderline malignant variants and aggressive malignant peritoneal mesothelioma (MPeM). This study retrospectively evaluates the efficacy of first-line systemic pemetrexed and cisplatin chemotherapy in MPeM. RESEARCH DESIGN AND METHODS: Twenty-four patients with histologically proven MPeM were treated with pemetrexed plus cisplatin as a first-line systemic chemotherapy...
June 15, 2017: Expert Review of Anticancer Therapy
https://www.readbyqxmd.com/read/28587731/prediction-of-clinical-outcome-using-blood-flow-volume-in-the-superior-mesenteric-artery-in-patients-with-pseudomyxoma-peritonei-treated-by-cytoreductive-surgery
#16
A Dohan, M Barral, C Eveno, R Lo Dico, R Kaci, A Pasteur-Rousseau, P Soyer, M Pocard, P Bonnin
BACKGROUND: Pseudomyxoma peritonei (PMP) is a rare carcinomatosis limited to the peritoneal cavity, mainly supplied by the superior mesenteric artery (SMA). The only curative treatment is cytoreductive surgery (CRS) associated with hyperthermic intraperitoneal chemotherapy. This study aimed to evaluate the ability of blood flow volume (BFV) recorded in the SMA using Doppler ultrasonography pre-operatively to predict the extent and resectability of the disease and post-operatively to assess clinical outcome...
May 25, 2017: European Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28579603/rapamycin-treatment-for-benign-multicystic-peritoneal-mesothelioma-a-rare-disease-with-a-difficult-management
#17
Giovanni Stallone, Barbara Infante, Luigi Cormio, Luca Macarini, Giuseppe Grandaliano
BACKGROUND Benign multicystic peritoneal mesothelioma (BMPM) is a rare intra-abdominal tumor. Although considered by many to be benign, this tumor has a high local recurrence rate. Because of its rarity, preoperative diagnosis is difficult and its origin and pathogenesis are uncertain. There are no evidence-based treatment strategies for BMPM. It is agreed that the best treatment strategy for BMPM is the combination of surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC). An increasing body of evidence supports a pivotal role of the cytoplasmic serine/threonine kinase mTOR in the development and progression of several neoplastic diseases and specific mTOR inhibitors, including rapamycin, have been suggested as potential therapeutic options for different cancers...
June 5, 2017: American Journal of Case Reports
https://www.readbyqxmd.com/read/28562119/cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy-for-peritoneal-malignancy-preliminary-results-of-a-multi-disciplinary-teamwork-model-in-asia
#18
Ting-Yao Wang, Chao-Yu Chen, Chang-Hsien Lu, Min-Chi Chen, Li-Wen Lee, Tzu-Hao Huang, Meng-Chiao Hsieh, Chih-Jung Chen, Chung-Ming Yu, Huei-Chieh Chuang, Tzu-Ting Liao, Chih-Wen Tseng, Wen-Shih Huang
BACKGROUND: Cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC) is an emerging surgical procedure for peritoneal carcinomatosis (PC). CRS/HIPEC is a complicated treatment that requires multi-disciplinary teamwork (MDT) which may be lacking when establishing a CRS/HIPEC program. Herein, we report our preliminary treatment outcomes with the early implementation of an MDT model for CRS/HIPEC. METHODS: From April 2015 to December 2016, 45 patients with a diagnosis of PC who received CRS/HIPEC were reviewed retrospectively in a single institution in Taiwan...
May 31, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28560703/allogenic-blood-transfusion-is-an-independent-predictor-of-poorer-peri-operative-outcomes-and-reduced-long-term-survival-after-cytoreductive-surgery-and-hyperthermic-intraperitoneal-chemotherapy-a-review-of-936-cases
#19
Akshat Saxena, Sarah J Valle, Winston Liauw, David L Morris
INTRODUCTION: There is a paucity of data on the impact of allogenic blood transfusion (ABT) on morbidity and survival outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). METHODS: Nine hundred and thirty-five consecutive CRS/HIPEC procedures were performed between 1996 and 2016 at a high-volume institution in Sydney, Australia. Of these, 337(36%) patients required massive ABT (MABT) (≥5 units). Peri-operative complications were graded according to the Clavien-Dindo classification...
May 30, 2017: Journal of Gastrointestinal Surgery: Official Journal of the Society for Surgery of the Alimentary Tract
https://www.readbyqxmd.com/read/28560593/base-excess-as-a-predictor-of-complications-in-cytoreductive-surgery-with-hyperthermic-intraperitoneal-chemotherapy
#20
Oliver S Eng, Sinziana Dumitra, Michael O'Leary, Mark Wakabayashi, Thanh H Dellinger, Ernest S Han, Stephen J Lee, I Benjamin Paz, Gagandeep Singh, Byrne Lee
BACKGROUND: Base excess is important in assessing metabolic status. Postoperative management in patients undergoing cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal malignancies can be a challenge, and we therefore sought to investigate perioperative predictors of overall morbidity in CRS/HIPEC patients at our institution. METHODS: Patients who underwent CRS/HIPEC from 2012 to 2016 were identified retrospectively from a prospectively collected institutional database...
May 30, 2017: Annals of Surgical Oncology
keyword
keyword
84002
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"